Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open labelled, prospective, multicenter observational study evaluating efficacy and safety of vasodilator beta-blocker Nebivolol in hypertensive patients

Next Previous
Trial Profile

An open labelled, prospective, multicenter observational study evaluating efficacy and safety of vasodilator beta-blocker Nebivolol in hypertensive patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Nebivolol (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BENEFIT-KOREA

    • Most Recent Events

    • 16 Oct 2018 New trial record
    • 09 Sep 2018 Results assessing efficacy and safety of vasodilator beta-blocker Nebivolol in elderly hypertensive patients (n=1655), presented at the Hypertension Scientific Session 2018
    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top